New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:40 EDTAMGN, BAYRYEMA backs expanded indication for Nexavar for thyroid cancer
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Nexavar. Nexavar is currently indicated for the treatment of patients with hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. The CHMP has now recommended an extension to the indication to include the treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine. Nexavar is marketed by Bayer (BAYRY) and Amgen's (AMGN) Onyx Pharmaceuticals.
News For AMGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
19:08 EDTAMGNAmgen announces publication of phase 3 studies, RUTHERFORD-2, TESLA
Subscribe for More Information
16:04 EDTAMGNAmgen to present present several studies related to brodalumab, Enbrel, ABP 501
Subscribe for More Information
11:34 EDTBAYRYMerck completes sale of Consumer Care business to Bayer $14.2B
Merck (MRK) said it has completed the previously announced sale of the Merck Consumer Care business to Bayer (BAYRY). Bayer will acquire Merck’s existing over-the-counter business, including the global trademark and prescription rights for CLARITINTM and AFRINTM, for $14.2B or approximately $9B in after-tax proceeds, less customary closing adjustments as well as certain contingent amounts held back that will be payable upon the manufacturing site transfer in Canada and regulatory approvals in Mexico and Korea. In conjunction with this transaction, Merck has also entered into the previously announced worldwide collaboration between the companies to develop and commercialize soluble guanylate cyclase modulators. This collaboration includes Bayer’s ADEMPASTM. The collaboration also includes opt-in rights for other early-stage sGC compounds in development by both companies. Merck will be making an upfront payment of $1B in connection with the sGC collaboration.
07:39 EDTAMGNAmgen reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 30, 2014
12:12 EDTBAYRYOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTBAYRYOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
07:30 EDTAMGNSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
07:26 EDTAMGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
11:25 EDTBAYRYBayer said to not plan spin-off of Agrochem unit, Bloomberg reports
Subscribe for More Information
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
September 23, 2014
09:00 EDTBAYRYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
05:17 EDTBAYRYRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use